CDK4 and breast cancer: To characterize and compare senescence induced by treatment with DNA‐damaging agents (Cisplatin and Doxorubicin) and CDK4/6i, we screened various breast cancer cell lines to find out which could achieve stable senescent status for analysis post‐drug treatment.